Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation
作者:Francesca Curreli、Shahad Ahmed、Sofia M. Benedict Victor、Ildar R. Iusupov、Dmitry S. Belov、Pavel O. Markov、Alexander V. Kurkin、Andrea Altieri、Asim K. Debnath
DOI:10.1021/acs.jmedchem.9b02149
日期:2020.2.27
inhibitory concentration of 89 nM. However, cytotoxicity remained high, and the absorption, distribution, metabolism, and excretion (ADME) data showed relatively poor aqueous solubility. To optimize these properties, we replaced the phenyl ring in the compound with a pyridine ring and synthesized a set of 48 novel compounds. One of the new analogues, NBD-14270 (8), showed a marked improvement in cytotoxicity
我们先前报道了开发新的新型类似物NBD-14189(Ref1),从而优化了HIV-1 gp120拮抗剂NBD-11021的里程碑,该类似物显示出对HIV-1HXB2的抗病毒活性,且最大抑制浓度为一半为89 nM。但是,细胞毒性仍然很高,吸收,分布,代谢和排泄(ADME)数据显示相对较差的水溶性。为了优化这些特性,我们用吡啶环取代了化合物中的苯环,并合成了48种新型化合物。一种新的类似物NBD-14270(8)表现出明显的细胞毒性改善,与Ref1和NBD-11021相比,选择性指数值分别提高了3倍和58倍。此外,体外ADME数据清楚地表明,与Ref1相比,水溶性和其他性能有所改善。8的数据表明吡啶骨架是苯基的良好生物等排体,从而允许对该分子的进一步优化。